Scarica l'app Stockscreener
41.35
0.29%
0.12
Dopo l'orario di chiusura:
41.35
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - Yahoo Finance UK
UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base - Yahoo Finance
Behavioral Patterns of URGN and Institutional Flows - Stock Traders Daily
UroGen Pharma (URGN) Stock Looks About Right As Sales Catch Up - simplywall.st
UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions? - Insider Monkey
URGN Stock Price, Quote & Chart - ChartMill
UroGen Pharma (URGN) Stock May Still Trade At A Discount To Sales - simplywall.st
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction By Investing.com - Investing.com India
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction - Investing.com
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com Nigeria
UroGen Pharma general counsel sells $64,618 in shares - Investing.com India
UroGen Pharma's General Counsel Reports RSU Vesting and Tax-Related Share Sale - Kalkine Media
UroGen at Wells Fargo conference: launch gains and pipeline widen By Investing.com - Investing.com Canada
UroGen Pharma general counsel sells $64,618 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com Canada
Tyra Biosciences Shares Tumble 22% as Bladder Cancer Drug Misses Efficacy Benchmark - finance.biggo.com
UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding - Stock Titan
UroGen Pharma advances with strong Zusduri sales and promising URGN-103 approval ahead - Pluang
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - Stock Titan
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - Stock Titan
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup - ChartMill
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
UroGen Pharma Ltd. (URGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nineteen new employees could receive up to 117,100 UroGen shares over three years. - Stock Titan
UroGen Pharma Ltd. (URGN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Trading the Move, Not the Narrative: (URGN) Edition - Stock Traders Daily
UroGen Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
IntraGel Therapeutics Receives $7M Investment From UroGen Pharma - FinSMEs
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - Sahm
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - Sahm
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionEarnings Manipulation Risk - careplusvn.com
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - Sahm
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet - Yahoo Finance
UroGen Pharma inks licensing deal with IntraGel Therapeutics - The Pharma Letter
UroGen Pharma Enters Option and Investment Deal with IntraGel Therapeutics - Kalkine Media
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more - Stock Titan
Cancer treatment co UroGen invests $7m in Israel’s IntraGelGlobes - Globes - Israel Business News
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. - marketscreener.com
UroGen Pharma secures option deal with IntraGel for cancer tech By Investing.com - Investing.com Nigeria
IntraGel secures $7M from UroGen for cancer therapy development By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing By Investing.com - Investing.com Canada
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform - marketscreener.com
URGN Looks 90.6% Overvalued on GF Value™ - GuruFocus
UroGen inks equity and option deals with IntraGel (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment - TradingView
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - The Manila Times
IntraGel's head and neck cancer drug study gets up to $7 million for Phase 2 - Stock Titan
UroGen gets an exclusive option on TumoCure after Phase 2 - Stock Titan
Urogen Pharma stock hits 52-week high at 49.69 USD By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Urogen Pharma stock hits 52-week high at 49.69 USD - Investing.com
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):